Equities research analysts expect Alphatec Holdings Inc (NASDAQ:ATEC) to report earnings per share (EPS) of ($0.12) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Alphatec’s earnings. Alphatec reported earnings per share of $0.39 during the same quarter last year, which indicates a negative year over year growth rate of 130.8%. The company is expected to issue its next earnings report on Thursday, March 14th.
On average, analysts expect that Alphatec will report full year earnings of ($0.67) per share for the current fiscal year. For the next financial year, analysts forecast that the firm will report earnings of ($0.45) per share. Zacks’ EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for Alphatec.
Alphatec (NASDAQ:ATEC) last announced its quarterly earnings data on Thursday, November 8th. The medical technology company reported ($0.22) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.09). Alphatec had a negative net margin of 10.03% and a negative return on equity of 78.46%. The business had revenue of $23.00 million during the quarter, compared to analysts’ expectations of $23.92 million.
A number of brokerages recently weighed in on ATEC. Zacks Investment Research downgraded shares of Alphatec from a “hold” rating to a “strong sell” rating in a report on Thursday, November 15th. HC Wainwright restated a “buy” rating and issued a $4.00 price objective on shares of Alphatec in a research report on Monday, November 12th. Finally, ValuEngine upgraded shares of Alphatec from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd.
Shares of ATEC traded down $0.05 on Thursday, reaching $2.00. The stock had a trading volume of 6,445 shares, compared to its average volume of 78,500. The stock has a market cap of $95.07 million, a P/E ratio of -5.56 and a beta of 1.35. The company has a debt-to-equity ratio of 1.42, a current ratio of 2.36 and a quick ratio of 1.48. Alphatec has a twelve month low of $2.01 and a twelve month high of $4.21.
Several institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC increased its stake in Alphatec by 29.4% in the 2nd quarter. Renaissance Technologies LLC now owns 484,645 shares of the medical technology company’s stock worth $1,444,000 after acquiring an additional 110,058 shares during the last quarter. PNC Financial Services Group Inc. acquired a new position in shares of Alphatec in the third quarter valued at about $548,000. Fondren Management LP increased its holdings in shares of Alphatec by 74.3% in the second quarter. Fondren Management LP now owns 375,223 shares of the medical technology company’s stock valued at $1,118,000 after purchasing an additional 160,000 shares during the period. Macquarie Group Ltd. acquired a new position in shares of Alphatec in the second quarter valued at about $116,000. Finally, BlackRock Inc. increased its holdings in shares of Alphatec by 32.9% in the second quarter. BlackRock Inc. now owns 196,555 shares of the medical technology company’s stock valued at $585,000 after purchasing an additional 48,688 shares during the period. 21.20% of the stock is currently owned by institutional investors.
Alphatec Holdings, Inc, a medical technology company, focuses on the design, development, and promotion of products for the surgical treatment of spine disorders. Its product portfolio and pipeline address the cervical, thoracolumbar, and intervertebral regions of the spine; and cover various spinal disorders and surgical procedures.
Featured Story: What are different types of coverage ratios?
Get a free copy of the Zacks research report on Alphatec (ATEC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.